Enanta Pharmaceuticals In... (ENTA)
NASDAQ: ENTA
· Real-Time Price · USD
6.01
0.08 (1.35%)
At close: Jun 02, 2025, 10:33 AM
1.35% (1D)
| Bid | 5.91 |
| Market Cap | 128.58M |
| Revenue (ttm) | 64.46M |
| Net Income (ttm) | -96.42M |
| EPS (ttm) | -4.53 |
| PE Ratio (ttm) | -1.33 |
| Forward PE | -1.93 |
| Analyst | Buy |
| Ask | 6.12 |
| Volume | 10,625 |
| Avg. Volume (20D) | 202,692 |
| Open | 5.99 |
| Previous Close | 5.93 |
| Day's Range | 5.88 - 6.05 |
| 52-Week Range | 4.09 - 17.23 |
| Beta | 0.82 |
About ENTA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ENTA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ENTA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
+14.08%
Enanta Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
5 months ago
+11.75%
Enanta Pharmaceuticals shares are trading higher after the company announced topeline results from its first-in-pediatrics Phase 2 study evaluating Zelicapavir for children aged 28 days to 36 months with respiratory syncytial vrius.
